High-dose daunorubicin (DNR) for induction and treatment of relapse in acute promyelocytic leukemia (APL): Report of 17 cases

E. B. Pallavicini, P. Luriri, L. Anselmetti, M. Gorini, R. Invernizzi, E. Ascari

Research output: Contribution to journalArticle

Abstract

Seventeen patients with acute promyelocytic leukemia (APL) were treated with high doses of Daunorubicin (DNR). Fourteen achieved complete remission (CR) but six relapsed after 9 to 46 months. Five of these six patients were treated again with DNR (2 mg/Kg/day for five days) and achieved a second complete and long-lasting remission. The sixth patient, who received Amsacrine, Vincristine, Cytarabine, achieved only a partial remission and subsequently died 6 months from the onset of relapse. None of the patients treated with DNR showed any signs of irreversible cardiotoxicity due to the drug. The five-year survival rate for all 17 patients was 62.5 percent. The results we obtained confirm that DNR is of extreme benefit in the treatment of APL in relapse and that there is no development of resistance to the drug.

Original languageEnglish
Pages (from-to)49-53
Number of pages5
JournalHaematologica
Volume73
Issue number1
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'High-dose daunorubicin (DNR) for induction and treatment of relapse in acute promyelocytic leukemia (APL): Report of 17 cases'. Together they form a unique fingerprint.

  • Cite this

    Pallavicini, E. B., Luriri, P., Anselmetti, L., Gorini, M., Invernizzi, R., & Ascari, E. (1988). High-dose daunorubicin (DNR) for induction and treatment of relapse in acute promyelocytic leukemia (APL): Report of 17 cases. Haematologica, 73(1), 49-53.